Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026

The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASH New post hoc data from ESSENCE examines changes in liver related parameters with semaglutide 2.4 mg vs placebo in people with MASH and a BMI below 27 kg/m² Four posters, including one oral presentation, on investigational efruxifermin research and new analyses from the phase 2b SYMMETRY trial in compensated MASH cirrhosis PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct.